Income statement revenue $707.33M (+17.2% YoY).Operating income $146.82M (+16.2% YoY).Pre-tax result $151.66M (+21.8% YoY).Net result $121.36M (+34.5% YoY).

Antiviral And Anti Infective: $37.77M (+29.8% YoY)
Cardiology: $59.98M (+2.4% YoY)
Central Nervous System: $82.86M (+35.5% YoY)
Metabolic: $219.07M (+48.1% YoY)
Oncology: $209.37M (+11.0% YoY)
Other: $98.28M (-16.8% YoY)
Total direct costs: $505.69M (+19.5% YoY)
Selling, general and administrative: $48.1M (+3.1% YoY)
Depreciation: $6.56M (-3.3% YoY)
Amortization: $155K (-34.6% YoY)
Other income: $4.84M
Income tax expense: $30.3M (-11.6% YoY)

Loading financials

Income statement income statement flow. Revenue $707.33M. Net result $121.36M.

Income statement revenue $707.33M (+17.2% YoY).Operating income $146.82M (+16.2% YoY).Pre-tax result $151.66M (+21.8% YoY).Net result $121.36M (+34.5% YoY).

Antiviral And Anti Infective: $37.77M (+29.8% YoY)
Cardiology: $59.98M (+2.4% YoY)
Central Nervous System: $82.86M (+35.5% YoY)
Metabolic: $219.07M (+48.1% YoY)
Oncology: $209.37M (+11.0% YoY)
Other: $98.28M (-16.8% YoY)
Total direct costs: $505.69M (+19.5% YoY)
Selling, general and administrative: $48.1M (+3.1% YoY)
Depreciation: $6.56M (-3.3% YoY)
Amortization: $155K (-34.6% YoY)
Other income: $4.84M
Income tax expense: $30.3M (-11.6% YoY)